View profile

FarmaKology Newsletter - Issue #51

Revue
 
Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
 

FarmaKology

June 26 · Issue #51 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+5757 Subscribers ) !

Today's Startup
Neuroflow
Neuroflow
NeuroFlow
NeuroFlow promotes behavioral health access and engagement in all care settings to improve outcomes, overall wellness, and cost of care. Our suite of tools enables remote monitoring and behavioral health integration across the continuum of care, including psychology, primary care, and pain management settings. NeuroFlow’s mission is to be a resource and asset to health care providers in their tireless pursuit to help patients feel better faster.
News
Allergan, an AbbVie Company, and Molecular Partners , a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, a novel, investigational DARPin® therapy for patients with neovascular age-related macular degeneration .The letter from the FDA indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2 mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular age-related macular degeneration . AbbVie plans to meet with the FDA to discuss their comments and determine next steps.
Moderna, Inc. , a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. , the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.
Celltex, a Houston, Texas-based biotechnology company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells Against Coronavirus Disease 2019 (COVID-19).
The Saskatchewan Health Authority (SHA) says it is considering joining several clinical trials for COVID-19 medications, but is not currently using or testing any medications during patient treatment.Management of COVID-19 cases in Saskatchewan currently consists of two types of care — supportive and advanced — neither of which involves the use of medication. “Despite lots of interest and activity, no specific medications or interventions have been proven to safely treat COVID-19,” said the SHA in a written response to questions.
Research & Study
Podcast
Episode 59: Using Tau To Target Alzheimer’s Pharm Exec podcast
Job Opportunities
Upcoming Webinar
Video
Biologist says young people are fueling Covid-19 pandemic
FarmaKology
FarmaKology
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue